C4 Therapeutics (CCCC) Competitors

$3.08 -0.23 (-6.95%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.07 -0.01 (-0.32%)

As of 05:50 AM Eastern

CCCC vs. IMCR, FBRX, TSHA, ANAB, and NTLA

Should you buy C4 Therapeutics stock or one of its competitors? C4 Therapeutics's main competitors and comparable companies include Immunocore (IMCR), Forte Biosciences (FBRX), Taysha Gene Therapies (TSHA), AnaptysBio (ANAB), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does C4 Therapeutics compare to Immunocore?

C4 Therapeutics (NASDAQ:CCCC) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Immunocore had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 2 mentions for Immunocore and 0 mentions for C4 Therapeutics. Immunocore's average media sentiment score of 0.59 beat C4 Therapeutics' score of -1.00 indicating that Immunocore is being referred to more favorably in the news media.

Company	Overall Sentiment
C4 Therapeutics	Negative
Immunocore	Positive

C4 Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 127.27%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 78.74%. Given C4 Therapeutics' higher possible upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immunocore has higher revenue and earnings than C4 Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.04M	10.81	-$104.99M	-$1.00	N/A
Immunocore	$430.78M	3.77	-$35.51M	-$0.37	N/A

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Immunocore has a net margin of -4.20% compared to C4 Therapeutics' net margin of -289.44%. Immunocore's return on equity of -4.54% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Immunocore	-4.20%	-4.54%	-1.66%

C4 Therapeutics has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Summary

Immunocore beats C4 Therapeutics on 13 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

Forte Biosciences presently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. C4 Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 127.27%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Forte Biosciences has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market.

Forte Biosciences has higher earnings, but lower revenue than C4 Therapeutics. Forte Biosciences is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
C4 Therapeutics	$35.04M	10.81	-$104.99M	-$1.00	N/A

Forte Biosciences has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

In the previous week, Forte Biosciences' average media sentiment score of 0.00 beat C4 Therapeutics' score of -1.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Neutral
C4 Therapeutics	Negative

Summary

C4 Therapeutics beats Forte Biosciences on 11 of the 14 factors compared between the two stocks.

How does C4 Therapeutics compare to Taysha Gene Therapies?

C4 Therapeutics (NASDAQ:CCCC) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Taysha Gene Therapies had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for Taysha Gene Therapies and 0 mentions for C4 Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.40 beat C4 Therapeutics' score of -1.00 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
C4 Therapeutics	Negative
Taysha Gene Therapies	Neutral

Taysha Gene Therapies has a net margin of 0.00% compared to C4 Therapeutics' net margin of -289.44%. C4 Therapeutics' return on equity of -45.45% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-289.44%	-45.45%	-30.90%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

C4 Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 127.27%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 160.07%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

C4 Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.04M	10.81	-$104.99M	-$1.00	N/A
Taysha Gene Therapies	$5.49M	291.68	-$109M	-$0.42	N/A

C4 Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Summary

Taysha Gene Therapies beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

AnaptysBio presently has a consensus target price of $79.15, suggesting a potential upside of 55.91%. C4 Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 127.27%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

AnaptysBio has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.41	-$13.23M	$5.37	9.45
C4 Therapeutics	$35.04M	10.81	-$104.99M	-$1.00	N/A

AnaptysBio has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, meaning that its share price is 194% more volatile than the broader market.

In the previous week, AnaptysBio had 18 more articles in the media than C4 Therapeutics. MarketBeat recorded 18 mentions for AnaptysBio and 0 mentions for C4 Therapeutics. AnaptysBio's average media sentiment score of 0.52 beat C4 Therapeutics' score of -1.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Overall Sentiment
AnaptysBio	Positive
C4 Therapeutics	Negative

78.8% of C4 Therapeutics shares are held by institutional investors. 31.5% of AnaptysBio shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AnaptysBio has a net margin of 82.37% compared to C4 Therapeutics' net margin of -289.44%. AnaptysBio's return on equity of 112.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Summary

AnaptysBio beats C4 Therapeutics on 12 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Intellia Therapeutics had 5 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 0 mentions for C4 Therapeutics. Intellia Therapeutics' average media sentiment score of 0.29 beat C4 Therapeutics' score of -1.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Neutral
C4 Therapeutics	Negative

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

C4 Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	25.53	-$412.69M	-$3.36	N/A
C4 Therapeutics	$35.04M	10.81	-$104.99M	-$1.00	N/A

C4 Therapeutics has a net margin of -289.44% compared to Intellia Therapeutics' net margin of -672.16%. C4 Therapeutics' return on equity of -45.45% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
C4 Therapeutics	-289.44%	-45.45%	-30.90%

Intellia Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.94, meaning that its stock price is 194% more volatile than the broader market.

Intellia Therapeutics presently has a consensus target price of $20.98, indicating a potential upside of 70.14%. C4 Therapeutics has a consensus target price of $7.00, indicating a potential upside of 127.27%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
C4 Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

C4 Therapeutics beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$407.21M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-3.08	13.88	274.08	25.69
Price / Sales	10.81	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.16	15.40	10.47	6.32
Net Income	-$104.99M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-9.68%	-1.70%	-0.67%	0.17%
1 Month Performance	-24.88%	-6.17%	-3.17%	-3.27%
1 Year Performance	27.27%	30.67%	15.14%	5.58%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.3439 of 5 stars	$3.08 -6.9%	$7.00 +127.3%	+18.9%	$407.21M	$35.04M	N/A	104	Negative News High Trading Volume
IMCR Immunocore	3.451 of 5 stars	$31.64 -2.5%	$56.38 +78.2%	-8.4%	$1.64B	$430.78M	N/A	524
FBRX Forte Biosciences	0.9866 of 5 stars	$76.99 flat	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5
TSHA Taysha Gene Therapies	2.915 of 5 stars	$5.01 -0.1%	$12.77 +155.1%	+68.2%	$1.63B	$5.49M	N/A	99	Positive News Analyst Forecast
ANAB AnaptysBio	3.4539 of 5 stars	$54.97 +1.6%	$79.85 +45.2%	+142.3%	$1.62B	$234.60M	N/A	104	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. IMCR, FBRX, TSHA, ANAB, and NTLA

How does C4 Therapeutics compare to Immunocore?

Summary

How does C4 Therapeutics compare to Forte Biosciences?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Summary

How does C4 Therapeutics compare to AnaptysBio?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. IMCR, FBRX, TSHA, ANAB, and NTLA

How does C4 Therapeutics compare to Immunocore?

Does the media favor CCCC or IMCR?

Do analysts prefer CCCC or IMCR?

Which has higher valuation and earnings, CCCC or IMCR?

Do insiders & institutionals have more ownership in CCCC or IMCR?

Is CCCC or IMCR more profitable?

Which has more risk and volatility, CCCC or IMCR?

Summary

How does C4 Therapeutics compare to Forte Biosciences?

Do analysts recommend FBRX or CCCC?

Do institutionals and insiders believe in FBRX or CCCC?

Which has more volatility and risk, FBRX or CCCC?

Which has higher valuation & earnings, FBRX or CCCC?

Is FBRX or CCCC more profitable?

Does the media refer more to FBRX or CCCC?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Does the media favor CCCC or TSHA?

Is CCCC or TSHA more profitable?

Do insiders and institutionals hold more shares of CCCC or TSHA?

Do analysts recommend CCCC or TSHA?

Which has better valuation and earnings, CCCC or TSHA?

Which has more volatility & risk, CCCC or TSHA?

Summary

How does C4 Therapeutics compare to AnaptysBio?

Do analysts rate ANAB or CCCC?

Which has stronger valuation & earnings, ANAB or CCCC?

Which has more risk & volatility, ANAB or CCCC?

Does the media refer more to ANAB or CCCC?

Do institutionals and insiders hold more shares of ANAB or CCCC?

Is ANAB or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Intellia Therapeutics?

Does the media refer more to NTLA or CCCC?

Do institutionals and insiders believe in NTLA or CCCC?

Which has preferable valuation and earnings, NTLA or CCCC?

Is NTLA or CCCC more profitable?

Which has more volatility and risk, NTLA or CCCC?

Do analysts prefer NTLA or CCCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools